Citron

GameStop's Short Squeeze Anniversary: A Look Back At David Vs. Goliath Battle And What's Next (CORRECTED)

'So Much Is Wrong:' Short-Seller Andrew Left Says 'Roaring Kitty' Trying To Take Advantage Of Retail Traders After Revealing Huge GameStop Position

The 'Most Ridiculous IPO' Of 2020? Citron Hits DoorDash With $40 Target

'So Much Is Wrong:' Short-Seller Andrew Left Says 'Roaring Kitty' Trying To Take Advantage Of Retail Traders After Revealing Huge GameStop Position

The 'Most Ridiculous IPO' Of 2020? Citron Hits DoorDash With $40 Target

Citron Research Says Tesla Shares Are Doing 'Too Much Too Fast'

Citron Thinks Peloton's Stock Is Going To $5, Compares It To GoPro

Citron Research Says Tesla Shares Are Doing 'Too Much Too Fast'

|

Citron Thinks Peloton's Stock Is Going To $5, Compares It To GoPro

|

Citron Claims Alexandria Ocasio-Cortez Is Just What Twitter Needs

|

Cronos Group, Analyst Respond To Citron's Short Report

|

Citron Recent News

PolarityTE's Stock Falls 30% After Citron Calls It A Fraud

|

The Long And The Short Of It: Bitcoin Bull, Bear Weigh In On Huge Move

|

Veritone Comes Crashing Back To Earth

|

'All Timing': Citron Covers Helios And Matheson Short

|

The Polarizing Story That Is Shopify

|

Citron's Andrew Left Hits The Airwaves To Explain His Bullish BlackBerry Stance

|

Andrew Left Doubles Down On Wayfair Thesis

|

Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups

|

Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen

|

Mallinckrodt Spikes On Citron Tweet

|

Citron: Mallinckrodt Makes Valeant Look Like Choirboys

|

Buy The Dip In j2 Global, Susquehanna Says

|

Fitbit On The Rise As Citron Comes Out Positive

|

Tesla Short Sellers Paying Much Higher Interest To Bet Against Company

|

Tesla's Apparent Oil Correlation Doesn't Make Stock A Buy: Why Citron Is Short

|

Valeant Gets Closer To Left's $50 Target After New Accounting Fears

|

Critical Of Monster's Valuation, Citron Anticipates A Drop To $80

|

EXCLUSIVE: Philidor Calls Short-Sellers 'Discredited' And 'Patently False'; Citron's Andrew Left Responds

|

JPMorgan Analyst Defends Valeant, Cites Continued Performance Of Two-Thirds Revenue

|

Mallinckrodt The Latest To Feel Citron's Wrath, Has Significantly More Downside Than Valeant

|

Valeant Pharmaceuticals Trading Higher

|

Valeant Denies Citron's 'Erroneous' Report; Analysts Also Cast Doubt

|

Citron Calls Valeant The 'Pharmaceutical Enron,' Sees 60% Downside In Stock

|